
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4475154/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The P2X7 Receptor in Infection and Inflammation. Immunity, 2017, 47, 15-31.	6.6	853
2	Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease. Neuropharmacology, 2021, 190, 108352.	2.0	386
3	P2X7 Receptor as a Therapeutic Target. Advances in Protein Chemistry and Structural Biology, 2016, 104, 39-79.	1.0	88
4	Synthesis and Biological Evaluation of a New Set of Pyrazolo[1,5-c]quinazoline-2-carboxylates as Novel Excitatory Amino Acid Antagonists. Journal of Medicinal Chemistry, 2002, 45, 1035-1044.	2.9	80
5	Competitive AMPA receptor antagonists. Medicinal Research Reviews, 2007, 27, 239-278.	5.0	77
6	Synthesis and Structureâ^'Activity Relationships of a New Set of 2-Arylpyrazolo[3,4-c]quinoline Derivatives as Adenosine Receptor Antagonists. Journal of Medicinal Chemistry, 2000, 43, 3118-3124.	2.9	75
7	1,2,4-Triazolo[4,3-a]quinoxalin-1-one Moiety as an Attractive Scaffold To Develop New Potent and Selective Human A3Adenosine Receptor Antagonists:Â Synthesis, Pharmacological, and Ligandâ^'Receptor Modeling Studies. Journal of Medicinal Chemistry, 2004, 47, 3580-3590.	2.9	67
8	1-Substituted pyrazolo[1,5-c]quinazolines as novel Gly/NMDA receptor antagonists: Synthesis, biological evaluation, and molecular modeling study. Bioorganic and Medicinal Chemistry, 2005, 13, 5536-5549.	1.4	64
9	1,2,4-Triazolo[4,3-a]quinoxalin-1-one:Â A Versatile Tool for the Synthesis of Potent and Selective Adenosine Receptor Antagonists. Journal of Medicinal Chemistry, 2000, 43, 1158-1164.	2.9	61
10	New 2-Arylpyrazolo[3,4- <i>c</i> ]quinoline Derivatives as Potent and Selective Human A <sub>3</sub> Adenosine Receptor Antagonists. Synthesis, Pharmacological Evaluation, and Ligandâ^'Receptor Modeling Studies. Journal of Medicinal Chemistry, 2007, 50, 4061-4074.	2.9	58
11	The Identification of the 2-Phenylphthalazin-1(2 <i>H</i> )-one Scaffold as a New Decorable Core Skeleton for the Design of Potent and Selective Human A <sub>3</sub> Adenosine Receptor Antagonists. Journal of Medicinal Chemistry, 2011, 54, 2102-2113.	2.9	57
12	4-Amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as New Potent and Selective Human A3Adenosine Receptor Antagonists. Synthesis, Pharmacological Evaluation, and Ligandâ^'Receptor Modeling Studies. Journal of Medicinal Chemistry, 2006, 49, 3916-3925.	2.9	56
13	1,2,4-Triazolo[1,5-a]quinoxaline as a Versatile Tool for the Design of Selective Human A3 Adenosine Receptor Antagonists:  Synthesis, Biological Evaluation, and Molecular Modeling Studies of 2-(Hetero)aryl- and 2-Carboxy-Substitued Derivatives. Journal of Medicinal Chemistry, 2005, 48, 7932-7945.	2.9	52
14	2-Phenylpyrazolo[4,3- <i>d</i> ]pyrimidin-7-one as a New Scaffold To Obtain Potent and Selective Human A <sub>3</sub> Adenosine Receptor Antagonists: New Insights into the Receptorâ^'Antagonist Recognition. Journal of Medicinal Chemistry, 2009, 52, 7640-7652.	2.9	51
15	Design, synthesis and evaluation in an LPS rodent model of neuroinflammation of a novel 18F-labelled PET tracer targeting P2X7. EJNMMI Research, 2017, 7, 31.	1.1	50
16	Design, Synthesis, and Pharmacological Characterization of 2-(2-Furanyl)thiazolo[5,4- <i>d</i> ]pyrimidine-5,7-diamine Derivatives: New Highly Potent A <sub>2A</sub> Adenosine Receptor Inverse Agonists with Antinociceptive Activity. Journal of Medicinal Chemistry, 2016, 59, 10564-10576.	2.9	49
17	Structural Investigation of the 7-Chloro-3-hydroxy-1H-quinazoline-2,4-dione Scaffold to Obtain AMPA and Kainate Receptor Selective Antagonists. Synthesis, Pharmacological, and Molecular Modeling Studies. Journal of Medicinal Chemistry, 2006, 49, 6015-6026.	2.9	48
18	Inhibition of A2A Adenosine Receptor Signaling in Cancer Cells Proliferation by the Novel Antagonist TP455. Frontiers in Pharmacology, 2017, 8, 888.	1.6	48

#	Article	IF	CITATIONS
19	Synthesis and Biological Evaluation of Analogues of 7-Chloro-4,5-dihydro-4- oxo-8-(1,2,4-triazol-4-yl)-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylic Acid (TQX-173) as Novel Selective AMPA Receptor Antagonists. Journal of Medicinal Chemistry, 2004, 47, 262-272.	2.9	46
20	Innovative functional cAMP assay for studying G protein-coupled receptors: application to the pharmacological characterization of GPR17. Purinergic Signalling, 2011, 7, 463-468.	1.1	45
21	Structural investigations on coumarins leading to chromeno[4,3-c]pyrazol-4-ones and pyrano[4,3-c]pyrazol-4-ones: New scaffolds for the design of the tumor-associated carbonic anhydrase isoforms IX and XII. European Journal of Medicinal Chemistry, 2018, 146, 47-59.	2.6	45
22	Pyrazolo[1,5-c]quinazoline derivatives and their simplified analogues as adenosine receptor antagonists: Synthesis, structure–affinity relationships and molecular modeling studies. Bioorganic and Medicinal Chemistry, 2013, 21, 283-294.	1.4	43
23	Adenosine Receptor Modeling: What Does the A2A Crystal Structure Tell Us?. Current Topics in Medicinal Chemistry, 2010, 10, 993-1018.	1.0	42
24	Synthesis and Binding Activity of Some Pyrazolo[1,5-c]quinazolines as Tools To Verify an Optional Binding Site of a Benzodiazepine Receptor Ligand. Journal of Medicinal Chemistry, 1996, 39, 2915-2921.	2.9	41
25	Synthesis, Ionotropic Glutamate Receptor Binding Affinity, and Structureâ~'Activity Relationships of a New Set of 4,5-Dihydro-8-heteroaryl-4-oxo-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylates Analogues of TQX-173. Journal of Medicinal Chemistry, 2001, 44, 3157-3165.	2.9	41
26	Purinergic P2X receptors: Structural models and analysis ofÂligand-targetÂinteraction. European Journal of Medicinal Chemistry, 2015, 89, 561-580.	2.6	41
27	7-Chloro-4,5-dihydro-8-(1,2,4-triazol-4-yl)- 4-oxo-1,2,4-triazolo[1,5-a]quinoxaline-2- carboxylates as Novel Highly Selective AMPA Receptor Antagonists. Journal of Medicinal Chemistry, 2000, 43, 3824-3826.	2.9	39
28	Synthesis, ligand–receptor modeling studies and pharmacological evaluation of novel 4-modified-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent and selective human A3 adenosine receptor antagonists. Bioorganic and Medicinal Chemistry, 2008, 16, 6086-6102.	1.4	38
29	3-Hydroxy-quinazoline-2,4-dione as a useful scaffold to obtain selective Gly/NMDA and AMPA receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 2345-2349.	1.0	36
30	4,5-Dihydro-1,2,4-triazolo[1,5-a]quinoxalin-4-ones:  Excitatory Amino Acid Antagonists with Combined Glycine/NMDA and AMPA Receptor Affinity. Journal of Medicinal Chemistry, 1999, 42, 2478-2484.	2.9	35
31	Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a New Scaffold To Develop Potent and Selective Human A3 Adenosine Receptor Antagonists. Synthesis, Pharmacological Evaluation, and Ligandâ^'Receptor Modeling Studies. Journal of Medicinal Chemistry, 2009, 52, 2407-2419.	2.9	35
32	Synthesis of a set of ethyl 1-carbamoyl-3-oxoquinoxaline-2-carboxylates and of their constrained analogue imidazo[1,5-a]quinoxaline-1,3,4-triones as glycine/NMDA receptor antagonists. European Journal of Medicinal Chemistry, 2001, 36, 203-209.	2.6	33
33	2-Aryl-8-chloro-1,2,4-triazolo[1,5-a]quinoxalin-4-amines as highly potent A1 and A3 adenosine receptor antagonists. Bioorganic and Medicinal Chemistry, 2005, 13, 705-715.	1.4	33
34	Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications. Expert Opinion on Therapeutic Patents, 2019, 29, 943-963.	2.4	33
35	Synthesis and Biological Evaluation of a Series of Quinazoline-2-carboxylic Acids and Quinazoline-2,4-diones as Glycine-NMDA Antagonists: A Pharmacophore Model Based Approach. Archiv Der Pharmazie, 1997, 330, 129-134.	2.1	32
36	3-Hydroxy-1H-quinazoline-2,4-dione derivatives as new antagonists at ionotropic glutamate receptors: Molecular modeling and pharmacological studies. European Journal of Medicinal Chemistry, 2012, 54, 470-482.	2.6	31

#	Article	IF	CITATIONS
37	The 1,2,4-Triazolo[4,3- <i>a</i> ]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A <sub>2A</sub> Receptor Subtype. Journal of Medicinal Chemistry, 2017, 60, 5772-5790.	2.9	31
38	Scouting Human A3 Adenosine Receptor Antagonist Binding Mode Using a Molecular Simplification Approach: From Triazoloquinoxaline to a Pyrimidine Skeleton as a Key Study. Journal of Medicinal Chemistry, 2007, 50, 6596-6606.	2.9	30
39	The aminopyridine-3,5-dicarbonitrile core for the design of new non-nucleoside-like agonists of the human adenosine A2B receptor. European Journal of Medicinal Chemistry, 2018, 150, 127-139.	2.6	30
40	Synthesis and A1 and A2A adenosine binding activity of some pyrano[2,3-c]pyrazol-4-ones. Il Farmaco, 1998, 53, 189-196.	0.9	29
41	Synthesis and pharmacological studies at the Gly/NMDA, AMPA and Kainate receptors of new oxazolo[4,5-c]quinolin-4-one derivatives bearing different substituents at position-2 and on the fused benzo ring. European Journal of Medicinal Chemistry, 2005, 40, 897-907.	2.6	28
42	The Gâ€Protein oupled Receptor GPR17: Overview and Update. ChemMedChem, 2016, 11, 2567-2574.	1.6	28
43	Novel AMPA and kainate receptor antagonists containing the pyrazolo[1,5-c]quinazoline ring system: Synthesis and structure–activity relationships. Bioorganic and Medicinal Chemistry, 2008, 16, 2617-2626.	1.4	27
44	Adenosine Receptors as Neuroinflammation Modulators: Role of A1 Agonists and A2A Antagonists. Cells, 2020, 9, 1739.	1.8	27
45	Molecular modeling study on potent and selective adenosine A3 receptor agonists. Bioorganic and Medicinal Chemistry, 2010, 18, 7923-7930.	1.4	25
46	Synthesis of Some 2-Aryl-1,2,4-triazolo[1,5-c][1,3]benzoxazin-5-ones as Tools To Define the Essential Pharmacophoric Descriptors of a Benzodiazepine Receptor Ligand. Journal of Medicinal Chemistry, 1995, 38, 2196-2201.	2.9	24
47	2-Ary pyrazolo[4,3- <i>d</i> ]pyrimidin-7-amino Derivatives As New Potent and Selective Human A <sub>3</sub> Adenosine Receptor Antagonists. Molecular Modeling Studies and Pharmacological Evaluation. Journal of Medicinal Chemistry, 2013, 56, 2256-2269.	2.9	24
48	3-Hydroxy-1 <i>H</i> -quinazoline-2,4-dione as a New Scaffold To Develop Potent and Selective Inhibitors of the Tumor-Associated Carbonic Anhydrases IX and XII. Journal of Medicinal Chemistry, 2017, 60, 6428-6439.	2.9	24
49	Neuroprotective potential of adenosine A 1 receptor partial agonists in experimental models of cerebral ischemia. Journal of Neurochemistry, 2019, 149, 211-230.	2.1	24
50	Exploring the 7-oxo-thiazolo[5,4-d]pyrimidine core for the design of new human adenosine A3 receptor antagonists. Synthesis, molecular modeling studies and pharmacological evaluation. European Journal of Medicinal Chemistry, 2015, 96, 105-121.	2.6	23
51	Synthesis and structure–Activity relationships of a new set of 1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as adenosine receptor antagonists. Bioorganic and Medicinal Chemistry, 2003, 11, 3541-3550.	1.4	22
52	Simulation and comparative analysis of binding modes of nucleoside and non-nucleoside agonists at the A2B adenosine receptor. In Silico Pharmacology, 2013, 1, 24.	1.8	22
53	7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: Structural investigations at the 5-position to target human A1 and A2A adenosine receptors. Molecular modeling and pharmacological studies. European Journal of Medicinal Chemistry, 2014, 84, 614-627.	2.6	22
54	Adenosine A2B receptors inhibit K+ currents and cell differentiation in cultured oligodendrocyte precursor cells and modulate sphingosine-1-phosphate signaling pathway. Biochemical Pharmacology, 2020, 177, 113956.	2.0	22

FLAVIA VARANO

#	Article	IF	CITATIONS
55	Synthesis of 4-amino-6-(hetero)arylalkylamino-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent A2A adenosine receptor antagonists. Bioorganic and Medicinal Chemistry, 2003, 11, 5509-5518.	1.4	21
56	Competitive Gly/NMDA Receptor Antagonists. Current Topics in Medicinal Chemistry, 2006, 6, 809-821.	1.0	21
57	Novel potent and highly selective human A3 adenosine receptor antagonists belonging to the 4-amido-2-arylpyrazolo[3,4-c]quinoline series: Molecular docking analysis and pharmacological studies. Bioorganic and Medicinal Chemistry, 2009, 17, 401-410.	1.4	21
58	Synthesis, structure–affinity relationships, and molecular modeling studies of novel pyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists. Bioorganic and Medicinal Chemistry, 2011, 19, 3757-3768.	1.4	21
59	Antiproliferative Evaluation of Isofuranodiene on Breast and Prostate Cancer Cell Lines. Scientific World Journal, The, 2014, 2014, 1-6.	0.8	19
60	Different efficacy of adenosine and NECA derivatives at the human A3 adenosine receptor: Insight into the receptor activation switch. Biochemical Pharmacology, 2014, 87, 321-331.	2.0	19
61	1,2,4-Triazolo[1,5-a]quinoxaline derivatives and their simplified analogues as adenosine A3 receptor antagonists. Synthesis, structure–affinity relationships and molecular modeling studies. Bioorganic and Medicinal Chemistry, 2015, 23, 9-21.	1.4	18
62	Structural refinement of pyrazolo[4,3- d ]pyrimidine derivatives to obtain highly potent and selective antagonists for the human A 3 adenosine receptor. European Journal of Medicinal Chemistry, 2016, 108, 117-133.	2.6	18
63	Tricyclic heteroaromatic systems. Synthesis and benzodiazepine receptor affinity of 2-substituted-1-benzopyrano[3,4-d]oxazol-4-ones, -thiazol-4-ones, and -imidazol-4-ones. Il Farmaco, 1998, 53, 375-381.	0.9	17
64	Imidazo[1,2-a]pyrazin-8-amine core for the design of new adenosine receptor antagonists: Structural exploration to target the A3 and A2A subtypes. European Journal of Medicinal Chemistry, 2017, 125, 611-628.	2.6	17
65	Modifications on the Amino-3,5-dicyanopyridine Core To Obtain Multifaceted Adenosine Receptor Ligands with Antineuropathic Activity. Journal of Medicinal Chemistry, 2019, 62, 6894-6912.	2.9	16
66	Functional characterization of a novel adenosine A2B receptor agonist on short-term plasticity and synaptic inhibition during oxygen and glucose deprivation in the rat CA1 hippocampus. Brain Research Bulletin, 2019, 151, 174-180.	1.4	16
67	Tricyclic Heteroaromatic Systems. 1,2,4-Triazolo[4,3-a]quinoxalines and 1,2,4-Triazino[4,3-a]quinoxalines: Synthesis and Central Benzodiazepine Receptor Activity. Archiv Der Pharmazie, 1997, 330, 387-391.	2.1	15
68	Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases. Frontiers in Pharmacology, 2018, 9, 212.	1.6	15
69	Non-Nucleoside Agonists of the Adenosine Receptors: An Overview. Pharmaceuticals, 2019, 12, 150.	1.7	15
70	Antioxidant-Conjugated 1,2,4-Triazolo[4,3- <i>a</i> ]pyrazin-3-one Derivatives: Highly Potent and Selective Human A <sub>2A</sub> Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain. Journal of Medicinal Chemistry, 2019, 62, 8511-8531.	2.9	15
71	Neuropeptideâ€S Receptor: Recent Updates on Nonpeptide Antagonist Discovery. ChemMedChem, 2011, 6, 1163-1171.	1.6	14
72	8-(2-Furyl)adenine derivatives as A2A adenosine receptor ligands. European Journal of Medicinal Chemistry, 2013, 70, 525-535.	2.6	14

#	Article	IF	CITATIONS
73	Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors. Bioorganic and Medicinal Chemistry, 2016, 24, 2794-2808.	1.4	14
74	The role of 5-arylalkylamino- and 5-piperazino- moieties on the 7-aminopyrazolo[4,3- <i>d</i> ]pyrimidine core in affecting adenosine A <sub>1</sub> and A <sub>2A</sub> receptor affinity and selectivity profiles. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 248-263.	2.5	14
75	Identification of novel thiazolo[5,4-d]pyrimidine derivatives as human A1 and A2A adenosine receptor antagonists/inverse agonists. Bioorganic and Medicinal Chemistry, 2018, 26, 3688-3695.	1.4	14
76	Novel 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives as potent human adenosine A1 and A2A receptor antagonists. Evaluation of their protective effect against β-amyloid-induced neurotoxicity in SH-SY5Y cells. Bioorganic Chemistry, 2019, 87, 380-394.	2.0	14
77	1,2,4-Triazolo[1,5-a]quinoxaline derivatives: synthesis and biological evaluation as adenosine receptor antagonists. Il Farmaco, 2004, 59, 71-81.	0.9	13
78	The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A3 Receptor Agonist, in a Rat Model of Colitis. Cells, 2020, 9, 1509.	1.8	13
79	Combined Therapy of A1AR Agonists and A2AAR Antagonists in Neuroinflammation. Molecules, 2021, 26, 1188.	1.7	13
80	Emerging Roles of Purinergic Signaling in Diabetes. Medicinal Chemistry, 2018, 14, 428-438.	0.7	13
81	Structure-Activity Relationship Studies of Novel Pyrazolo[1,5-c][1,3]benzoxazines: Synthesis and Benzodiazepine Receptor Affinity. Archiv Der Pharmazie, 1996, 329, 529-534.	2.1	12
82	Tricyclic Heteroaromatic Systems. Pyrazolo[3,4-c]quinolin-4-ones and Pyrazolo[3,4-c]quinoline-1,4-diones: Synthesis and Benzodiazepine Receptor Activity. Archiv Der Pharmazie, 1997, 330, 383-386.	2.1	12
83	The Length and Flexibility of the 2â€6ubstituent of 9â€Ethyladenine Derivatives Modulate Affinity and Selectivity for the Human A <sub>2A</sub> Adenosine Receptor. ChemMedChem, 2016, 11, 1829-1839.	1.6	12
84	Structure-activity relationship studies and pharmacological characterization of N5-heteroarylalkyl-substituted-2-(2-furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine-based derivatives as inverse agonists at human A2A adenosine receptor. European Journal of Medicinal Chemistry, 2018, 155, 552-561.	2.6	12
85	Structural investigation on thiazolo[5,4-d]pyrimidines to obtain dual-acting blockers of CD73 and adenosine A2A receptor as potential antitumor agents. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127067.	1.0	12
86	P2X3 Receptor Ligands: Structural Features and Potential Therapeutic Applications. Frontiers in Pharmacology, 2021, 12, 653561.	1.6	12
87	Pyrazoloquinazoline Tricyclic System as Novel Scaffold to Design New Kinase CK2 Inhibitors. Letters in Drug Design and Discovery, 2006, 3, 281-284.	0.4	11
88	New potent and selective A1 adenosine receptor antagonists as potential tools for the treatment of gastrointestinal diseases. European Journal of Medicinal Chemistry, 2018, 151, 199-213.	2.6	11
89	Piperazine- and Piperidine-Containing Thiazolo[5,4-d]pyrimidine Derivatives as New Potent and Selective Adenosine A2A Receptor Inverse Agonists. Pharmaceuticals, 2020, 13, 161.	1.7	11
90	Synthesis and Biological Evaluation of a New Set of Pyrazolo[1,5-c]quinazolines as Glycine/N-Methyl-D-aspartic Acid Receptor Antagonists. Chemical and Pharmaceutical Bulletin, 2009, 57, 826-829.	0.6	10

#	Article	IF	CITATIONS
91	Stabilization of the cyclodecadiene derivative isofuranodiene by silver (I) coordination. Mechanistic and biological aspects. FA¬toterapA¬A¢, 2017, 117, 52-60.	1.1	10
92	2′,3′-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents. Purinergic Signalling, 2017, 13, 61-74.	1.1	10
93	Ex-vivo absorption study of lysine R-lipoate salt, a new pharmaceutical form of R-ALA. European Journal of Pharmaceutical Sciences, 2018, 118, 200-207.	1.9	10
94	Novel human adenosine receptor antagonists based on the 7-amino-thiazolo[5,4-d]pyrimidine scaffold. Structural investigations at the 2-, 5- and 7-positions to enhance affinity and tune selectivity. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 563-569.	1.0	10
95	Synthesis of 2-substituted-6,8-dichloro-3,4-dihydro-3-oxo-2H-1,4-benzothiazine-1,1-dioxides and -1-oxides as glycine-NMDA receptor antagonists. Il Farmaco, 1998, 53, 752-757.	0.9	9
96	Synthesis, Glycine/NMDA and AMPA Binding Activity of Some New 2,5,6-Trioxopyrazino[1,2,3-de]quinoxalines and of Their Restricted Analogs 2,5-Dioxo- and 4,5-Dioxoimidazo[1,5,4-de]quinoxalines. Archiv Der Pharmazie, 1999, 332, 201-207.	2.1	9
97	Amino-3,5-Dicyanopyridines Targeting the Adenosine Receptors. Ranging from Pan Ligands to Combined A1/A2B Partial Agonists. Pharmaceuticals, 2019, 12, 159.	1.7	9
98	GPR17 receptor modulators and their therapeutic implications: review of recent patents. Expert Opinion on Therapeutic Patents, 2019, 29, 85-95.	2.4	9
99	Discovery of first-in-class multi-target adenosine A2A receptor antagonists-carbonic anhydrase IX and XII inhibitors. 8-Amino-6-aryl-2-phenyl-1,2,4-triazolo [4,3-a]pyrazin-3-one derivatives as new potential antitumor agents. European Journal of Medicinal Chemistry, 2020, 201, 112478.	2.6	9
100	Approaches for designing and discovering purinergic drugs for gastrointestinal diseases. Expert Opinion on Drug Discovery, 2020, 15, 687-703.	2.5	9
101	A <sub>2A</sub> Adenosine Receptor Antagonists and their Potential in Neurological Disorders. Current Medicinal Chemistry, 2022, 29, 4780-4795.	1.2	9
102	Synthesis and Structure-Activity Relationships of 4-Cycloalkylamino-1, 2, 4-triazolo[4, 3-a]quinoxalin-1- one Derivatives as A1 and A3 Adenosine Receptor Antagonists. Archiv Der Pharmazie, 2004, 337, 35-41.	2.1	8
103	Simulation and Comparative Analysis of Different Binding Modes of Nonâ€nucleoside Agonists at the A <sub>2A</sub> Adenosine Receptor. Molecular Informatics, 2016, 35, 403-413.	1.4	8
104	Investigation on 2′,3′- <i>O</i> -Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists. ACS Medicinal Chemistry Letters, 2019, 10, 493-498.	1.3	8
105	Pharmacological Characterization of Some Selected 4,5-Dihydro-4-oxo-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylates and 3-Hydroxyquinazoline-2,4-diones as (S)-2-Amino-3-(3-hydroxy-5-methylisoxazol-4-yl)-propionic Acid Receptor Antagonists. Chemical and Pharmaceutical Bulletin. 2010. 58. 908-911.	0.6	7
106	1,2,4â€Benzothiadiazineâ€1,1â€dioxide Derivatives as Ionotropic Glutamate Receptor Ligands: Synthesis and Structure–Activity Relationships. Archiv Der Pharmazie, 2014, 347, 777-785.	2.1	7
107	A Novel Class of Dopamine D <sub>4</sub> Receptor Ligands Bearing an Imidazoline Nucleus. ChemMedChem, 2016, 11, 1819-1828.	1.6	7
108	Synthesis and Biological Evaluation of Novel 9-Heteroaryl Substituted 7-Chloro-4,5-dihydro-4-oxo-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylates (TQX) as (R,S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic Acid (AMPA) Receptor Antagonists. Chemical and Pharmaceutical Bulletin, 2008, 56, 1085-1091.	0.6	5

#	Article	IF	CITATIONS
109	Overview on Radiolabel-Free in vitro Assays for GPCRs. Mini-Reviews in Medicinal Chemistry, 2016, 17, 3-14.	1.1	5
110	Casein Kinase 1δ Inhibitors as Promising Therapeutic Agents for Neurodegenerative Disorders. Current Medicinal Chemistry, 2022, 29, 4698-4737.	1.2	5
111	A2A Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable?. Molecules, 2022, 27, 2386.	1.7	5
112	Development of novel pyridazinone-based adenosine receptor ligands. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1484-1489.	1.0	4
113	New A2A adenosine receptor antagonists: a structure-based upside-down interaction in the receptor cavity. Bioorganic Chemistry, 2019, 92, 103183.	2.0	4
114	New 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives. Evaluation of different moieties on the 6-aryl ring to obtain potent and selective human A2A adenosine receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127126.	1.0	4
115	Design and Synthesis of Novel Thiazolo[5,4-d]pyrimidine Derivatives with High Affinity for Both the Adenosine A1 and A2A Receptors, and Efficacy in Animal Models of Depression. Pharmaceuticals, 2021, 14, 657.	1.7	4
116	4-Heteroaryl Substituted Amino-3,5-Dicyanopyridines as New Adenosine Receptor Ligands: Novel Insights on Structure-Activity Relationships and Perspectives. Pharmaceuticals, 2022, 15, 478.	1.7	4
117	New sensible method to quantize the intestinal absorption of receptor ligands. Bioorganic and Medicinal Chemistry, 2019, 27, 3328-3333.	1.4	2
118	A3 Adenosine Receptor Antagonists with Nucleoside Structures and Their Anticancer Activity. Pharmaceuticals, 2022, 15, 164.	1.7	1
119	A patent review of adenosine A <sub>2B</sub> receptor antagonists (2016-present). Expert Opinion on Therapeutic Patents, 2022, 32, 689-712.	2.4	1
120	CK1 delta inhibition: an emerging strategy to combat neurodegenerative diseases. Future Medicinal Chemistry, 2022, 14, 1111-1113.	1.1	1
121	Special Issue "Adenosine Receptors as Attractive Targets in Human Diseases― Pharmaceuticals, 2021, 14, 140.	1.7	0
122	Purinergic P2X Receptors: Physiological and Pathological Roles and Potential as Therapeutic Targets. Current Medicinal Chemistry, 2014, , .	1.2	0